Eastern Cooperative Oncology Group Operations Office

东部肿瘤合作组运营办公室

• 批准号: 8543784
• 负责人: ROBERT L COMIS
• 金额: $ 13.96万
• 依托单位: FRONTIER SCI & TECHNOLOGY RSCH FDN, INC
• 依托单位国家: 美国
• 财政年份: 1992
• 资助国家: 美国
• 起止时间: 1992-09-01 至 2016-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8543784
• 关键词: Adult; Adverse event; Applications Grants; Cancer Patient; Clinical Trials; Correlative Study; Development; Eastern Cooperative Oncology Group; Funding; Goals; Grant; Group Meetings; Information Dissemination; Institution; Maintenance; Malignant Neoplasms; Manuals; Monitor; Organization administrative structures; Prevention; Principal Investigator; Procedures; Process; Program Development; Public Health; Publications; Quality Control; Records; Reporting; Request for Applications; Research; Research Personnel; Site; Structure; Therapeutic; Translational Research; Travel; improved; member; multidisciplinary; operation; programs; protocol development; standard of care

DESCRIPTION (Provided by applicant): The Eastern Cooperative Oncology Group (ECOG) is a multidisciplinary cancer clinical trials research group dedicated to the treatment, prevention, and cure of adult malignancies. The Operations Office grant application requests funding to support the activities of the group headquarters. Under the direction of the Principal Investigator, Robert L. Comis, MD, the ECOG Operations office is responsible for organizing and coordinating the scientific and administrative activities of the Group; these activities include protocol development, correlative study development, dissemination of necessary information to Group members, organization of Group meetings, maintenance of Group membership and publications, monitoring of compliance with regulatory requirements, adverse event (AE) reporting and review, administration of the audit program, the development and maintenance of standard operating procedures (SOPs), and the management and disbursement of Group funds. Funding requested by the ECOG Operations Office Grant includes support for the Chairs of the ECOG Scientific and Administrative Committees. Additionally funding is requested in this application for member institution accruals to therapeutic and non-therapeutic clinical trials. This application requests funding for the period 05/01/2010 - 04/30/2016. RELEVANCE: The primary goal of the ECOG Operations Office is to provide the support necessary to conduct relevant and rigorous clinical trials, which benefit public health by improving the quality and standard of care for cancer patients.

描述（由申请人提供）：东部合作肿瘤学组（ECOG）是一个多学科癌症临床试验研究小组，致力于治疗，预防和治愈成人恶性肿瘤。运营办公室授予申请要求资金支持集团总部的活动。在首席调查员罗伯特·L·科米斯（Robert L. Comis）的指导下，ECOG运营办公室负责组织和协调该集团的科学和行政活动；这些活动包括协议开发，相关研究的发展，向小组成员传播必要信息，组织会议的组织，团队成员资格和出版物的维护，监视对监管要求的遵守情况，不良事件（AE）报告和审查，审核计划的管理，开发和维护标准操作程序（SOP）（SOPS）（SOPS）以及集团的管理（SOP）。 ECOG运营办公室要求的资金包括对ECOG科学和行政委员会主席的支持。此外，在本申请中要求对会员机构进行治疗和非治疗临床试验的资金。该申请要求为2010年5月1日 - 2016年4月30日的期间提供资金。 相关性：ECOG运营办公室的主要目标是提供进行相关和严格的临床试验所需的支持，这些试验通过改善癌症患者的质量和护理标准来使公共卫生受益。

项目成果

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.

• DOI: 10.1056/nejmoa1803164
• 发表时间: 2018-07-12
• 期刊: The New England journal of medicine
• 作者: Francis PA;Pagani O;Fleming GF;Walley BA;Colleoni M;Láng I;Gómez HL;Tondini C;Ciruelos E;Burstein HJ;Bonnefoi HR;Bellet M;Martino S;Geyer CE Jr;Goetz MP;Stearns V;Pinotti G;Puglisi F;Spazzapan S;Climent MA;Pavesi L;Ruhstaller T;Davidson NE;Coleman R;Debled M;Buchholz S;Ingle JN;Winer EP;Maibach R;Rabaglio-Poretti M;Ruepp B;Di Leo A;Coates AS;Gelber RD;Goldhirsch A;Regan MM;SOFT and TEXT Investigators and the International Breast Cancer Study Group
• 通讯作者: SOFT and TEXT Investigators and the International Breast Cancer Study Group

Piritrexim in advanced, refractory carcinoma of the urothelium (E3896): a phase II trial of the Eastern Cooperative Oncology Group.

吡曲辛治疗晚期难治性尿路上皮癌 (E3896)：东部肿瘤合作组的一项 II 期试验。

• DOI: 10.1023/a:1020675017737
• 发表时间: 2002
• 期刊: Investigational new drugs
• 影响因子: 3.4
• 作者: Roth,BruceJ;Manola,Judith;Dreicer,Robert;Graham,David;Wilding,George;EasternCooperativeOncologyGroup
• 通讯作者: EasternCooperativeOncologyGroup

Phase II evaluation of menogaril in advanced prostate cancer: Eastern Cooperative Oncology Group EST P-A885.

Menogaril 在晚期前列腺癌中的 II 期评估：东部肿瘤合作组 EST P-A885。

• DOI: 10.1097/00000421-200104000-00011
• 发表时间: 2001
• 期刊: American journal of clinical oncology
• 作者: Obasaju,C;Manola,J;Hudes,GR;Khandekar,JD;Citrin,DL;Carbone,P;Trump,DL
• 通讯作者: Trump,DL

Rare adult acute lymphocytic leukemia with CD56 expression in the ECOG experience shows unexpected phenotypic and genotypic heterogeneity.

ECOG 经验中罕见的成人急性淋巴细胞白血病 CD56 表达表现出意想不到的表型和基因型异质性。

• DOI: 10.1002/1096-8652(200103)66:3
• 发表时间: 2001
• 期刊: American journal of hematology
• 影响因子: 12.8
• 作者: Paietta,E;Neuberg,D;Richards,S;Bennett,JM;Han,L;Racevskis,J;Dewald,G;Rowe,JM;Wiernik,PH;EasternCooperativeOncologyGroup
• 通讯作者: EasternCooperativeOncologyGroup

Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial.

• DOI: 10.1200/jco.2004.10.046
• 发表时间: 2004-03
• 期刊: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
• 作者: K. Tedesco;A. Thor;David H. Johnson;Y. Shyr;K. Blum;L. Goldstein;W. Gradishar;B. Nicholson;D. Merkel;D. Murrey;S. Edgerton;G. Sledge